Treatment options in postherpetic neuralgia

Area of Science:

• Neurology
• Pain Management
• Pharmacology

Background:

• Postherpetic neuralgia (PHN) is a chronic neuropathic pain condition resulting from acute herpes zoster.
• PHN involves abnormal somatosensory processing and is often resistant to treatments.
• Effective pharmacologic management for PHN remains challenging due to inhomogeneous patient responses.

Purpose of the Study:

• To review current treatment modalities for postherpetic neuralgia.
• To focus on mechanism-based pharmacologic interventions for PHN.
• To classify pharmacologic approaches based on their site of action.

Main Methods:

• Review of current literature on PHN treatments.
• Classification of drugs by mechanism: topical, nerve excitability/conduction, and central synaptic changes.
• Analysis of clinical trial data for various drug regimens.

Main Results:

• Tricyclic antidepressants (TCAs) are effective in about 50% of PHN patients but may be poorly tolerated in the elderly.
• Gabapentin shows efficacy and safety as a first-line oral medication for PHN, improving sleep and quality of life.
• Other supported treatments include topical/intravenous lidocaine, intravenous ketamine, carbamazepine, and opioids.

Conclusions:

• PHN treatment requires a tailored approach, often involving multidrug regimens if monotherapy fails.
• Mechanism-based pharmacologic interventions are crucial for managing this complex neuropathic pain.
• Gabapentin represents a promising first-line oral option for PHN, offering broader patient benefits.